PRME:NASDAQPrime Medicine, Inc. analysis
Data as of Oct 19, 2026 - not real-time
- Latest price
- $3.83
- Risk: high
- 9/10High risk
Summary
Prime Medicine, Inc. trades at $3.83, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Across the trailing 30 sessions it gained 3.4%. With RSI at 57.3 the momentum picture is neutral, alongside a bullish MACD signal. Recent trading has carved out support near $2.77 and resistance around $4.14.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 86.0% above where the shares trade now. Revenue is growing at 3.5%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 112.0%, a beta of 2.28 and a maximum drawdown of 56.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 89 on the fear-greed composite.
The horizons diverge: hold near-term but sell on a long view, at 4/10 conviction over the longer horizon.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 86.0% above where the shares trade now. Revenue is growing at 3.5%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 112.0%, a beta of 2.28 and a maximum drawdown of 56.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 89 on the fear-greed composite.
The horizons diverge: hold near-term but sell on a long view, at 4/10 conviction over the longer horizon.
Top market events
- -- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise,...
- -- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building...
- Investing.com -- Prime Medicine Inc NASDAQ:PRME shares gained over 12% in after-hours trading Thursday following the...
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading above the 200-day average of 3.48
- MACD momentum is positive
Medium term
1–3 yearsNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading above the 200-day average of 3.48
- Analyst targets imply +86.0% versus the current price
Long term
> 3 yearsCautious
Model confidence4/104 out of 10
Key factors
- Analyst targets imply +86.0% versus the current price
- Negative return on equity of -373.3%
- Negative free cash flow
Key metrics
Financial health
Revenue Growth3.50%
P/E Ratio-4.3
ROE-373.29%
ROA-46.52%
Debt/Equity282.54
P/B Ratio17.0
Op. Cash Flow$-156051008
Free Cash Flow$-75780000
Industry P/E31.4
Technical analysis
TrendBearish
RSI57.3
Support$2.77
Resistance$4.14
MA 20$3.34
MA 50$3.35
MA 200$3.48
MACDBullish
VolumeIncreasing
Fear & Greed Index88.82
Valuation
Target Price$7.11
Upside/Downside85.98%
GradeFair
TypeGrowth
Risk assessment
Beta2.28
Volatility111.97%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.